A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Idelalisib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 31 Jul 2021 This trial has been completed in Spain as per European Clinical Trials Database record.
- 12 Dec 2017 Results (n=853) of ad hoc analysis assessing rates of grade more than or equal to 3 transaminase elevation using patient data from this and other 5 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 24 Jun 2016 Status changed from active, no longer recruiting to discontinued.